Genocea Biosciences (GNCA) Receiving Somewhat Favorable News Coverage, Analysis Finds

News stories about Genocea Biosciences (NASDAQ:GNCA) have been trending somewhat positive this week, according to AlphaOne. AlphaOne, a service of Accern, scores the sentiment of media coverage by monitoring more than 20 million news and blog sources. AlphaOne ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Genocea Biosciences earned a news impact score of 0.01 on AlphaOne’s scale. AlphaOne also assigned press coverage about the biotechnology company an impact score of 96 out of 100, indicating that recent media coverage is extremely likely to have an effect on the stock’s share price in the next several days.

Here are some of the news stories that may have impacted Alpha One Sentiment Analysis’s analysis:

Several equities analysts recently issued reports on the stock. Needham & Company LLC lowered shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Friday, February 17th. Zacks Investment Research raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $6.75 price objective on the stock in a report on Tuesday. Finally, FBR & Co reaffirmed an “outperform” rating on shares of Genocea Biosciences in a report on Monday, January 23rd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Genocea Biosciences presently has an average rating of “Buy” and a consensus target price of $15.98.

Genocea Biosciences (NASDAQ:GNCA) traded up 0.33% during trading on Friday, reaching $6.02. 165,712 shares of the company’s stock traded hands. The company’s market cap is $171.58 million. Genocea Biosciences has a 12-month low of $3.28 and a 12-month high of $7.29. The company has a 50 day moving average price of $6.30 and a 200-day moving average price of $5.02.

Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings data on Thursday, May 4th. The biotechnology company reported ($0.48) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.06. On average, equities research analysts forecast that Genocea Biosciences will post ($1.89) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Genocea Biosciences (GNCA) Receiving Somewhat Favorable News Coverage, Analysis Finds” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at

About Genocea Biosciences

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

12 Month Chart for NASDAQ:GNCA

Receive News & Ratings for Genocea Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply